(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on outsourced, GMP-compliant, scalable protein production, custom expression, end-to-end services, single-use systems and regional sourcing.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Manufacturing Services Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Recombinant Proteins Manufacturing Services Market to Reach $7.12 Billion by 2030
The global recombinant proteins manufacturing services market is projected to expand rapidly, rising from $3.7 billion in 2025 to $4.21 billion in 2026 at a compound annual growth rate (CAGR) of 13.8%. The market is forecast to reach $7.12 billion by 2030, representing a CAGR of 14% during the forecast period.
Historic market growth has been supported by increased investment in biologics research, expanding academic protein studies, greater adoption of contract manufacturing models, rising monoclonal antibody development, and continued growth in biotechnology startups. Looking ahead, the expanding pipeline of protein therapeutics, increased outsourcing by pharmaceutical companies, demand for scalable bioprocessing, growth in clinical-stage biologics, and the need for regulatory-compliant production facilities are expected to accelerate recombinant protein manufacturing services market growth.
Key recombinant protein manufacturing trends include the expansion of outsourced protein production, growing demand for custom expression services, wider adoption of Good Manufacturing Practice protein manufacturing, and the emergence of integrated end-to-end service models. Manufacturers are also increasing their use of single-use bioprocess systems to improve production flexibility, reduce turnaround times, and support efficient scale-up across research, clinical, and commercial programs.
Rising demand for biopharmaceuticals and biosimilars remains a major market driver. The growing prevalence of cancer, autoimmune disorders, metabolic conditions, and other chronic or life-threatening diseases is increasing the need for targeted biologic therapies. Advances in biologic drug development and improved patient access across major healthcare markets are further strengthening demand.
Recombinant proteins manufacturing services help pharmaceutical and biotechnology companies accelerate product development through scalable, high-quality, and regulatory-compliant production. These services also support consistent commercial supply while reducing the need for companies to build and maintain specialized internal manufacturing infrastructure. According to GOV.UK, businesses in the biopharmaceutical subsector generated total turnover of $135.5 billion (£98.9 billion) during 2023-2024, an increase of 15% from the previous year.
Technological innovation is reshaping the competitive landscape, particularly in high-yield protein expression, process optimization, mammalian cell culture, and scalable manufacturing. Advanced platforms are helping service providers improve protein quality, preserve biological activity, increase yields, and shorten development timelines. Flexible systems that can move efficiently from small research batches to larger manufacturing volumes are becoming increasingly important to customers developing monoclonal antibodies and other protein-based therapeutics.
In September 2024, Axio BioPharma launched recombinant protein manufacturing services designed to support research-grade monoclonal antibody production and scalable mammalian protein expression. The platform accommodates production volumes ranging from laboratory-scale batches to larger systems while supporting consistent protein quality and biological activity during early-stage development.
Strategic acquisitions are also strengthening specialized capabilities in the recombinant proteins manufacturing services market. In April 2024, Sino Biological Inc. acquired SignalChem Biotech Inc. for an undisclosed amount. The transaction expanded Sino Biological's capabilities in kinase biology, signal transduction research, enzymatic tools, and drug discovery support while strengthening its international presence and custom recombinant protein manufacturing portfolio.
Tariffs on bioreactor equipment, chromatography systems, purification resins, single-use assemblies, and specialized laboratory consumables are increasing capital and operating expenses. Downstream processing operations are particularly exposed to higher import costs. Providers in import-dependent markets, especially Asia-Pacific and parts of Europe, face margin pressure and may pass a portion of these costs to customers through higher service fees. However, tariffs are also encouraging regional equipment sourcing, domestic supplier development, and investment in locally manufactured bioprocess components, strengthening regional biomanufacturing ecosystems.
Markets Covered:
1) By Service Type: Process Development; Upstream Manufacturing; Downstream Manufacturing; Analytical Development and Quality Control; Finish and Lyophilization
2) By Protein Type: Monoclonal Antibodies and Antibody Fragments; Vaccines and Viral Proteins; Enzymes and Growth Factors; Hormones and Cytokines; Other Therapeutic and Diagnostic Proteins
3) By Host Cell: Mammalian Cells; Bacterial Cells; Insect Cells; Yeast and Fungi; Other Host Cell
4) By Application: Therapeutics; Research and Development; Diagnostics; Other Applications
5) By End-User: Pharmaceutical and Biotechnology Companies; Academic and Research Institutes
Subsegments:
1) By Process Development: Cell Line Development; Expression System Optimization; Process Scale Up; Process Validation
2) By Upstream Manufacturing: Microbial Fermentation; Mammalian Cell Culture; Insect Cell Culture; Media and Feed Optimization
3) By Downstream Manufacturing: Protein Purification; Chromatography Processing; Filtration and Concentration; Viral Clearance
4) By Analytical Development and Quality Control: Method Development; Stability Testing; Purity and Potency Testing; Batch Release Testing
5) By Finish and Lyophilization: Sterile Filling; Freeze Drying; Packaging and Labeling; Storage and Distribution Preparation
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment